Bioventix (BVXP LN)

Analysis

Health Care • United Kingdom

Bioventix specializes in the development and commercial supply of high-affinity sheep monoclonal antibodies (SMAs) for use in immunodiagnostics, particularly in clinical diagnostics and drugs of abuse testing. These antibodies are beneficial for detecting targets present at low concentrations or small molecules. The company is headquartered in Farnham, Surrey, UK, and was founded in 2003.

Refresh

Exchange Announcement • 24 Jun 2026 22:10

Director Dealing

Exchange Announcement • 18 May 2026 14:45

Holding(s) in Company

Exchange Announcement • 28 Apr 2026 21:45

Director Dealing

Exchange Announcement • 20 Apr 2026 17:54

Share Options Awarded

Exchange Announcement • 13 Apr 2026 13:00

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00